~8.5M
de-identified multimodal records
Tempus Studies
Overview
Accelerate your clinical trials by leveraging our end to end solutions
We partner with forward-thinking life science companies to sponsor studies of their drugs, devices, and diagnostics, integrating our life science solutions to help achieve their objectives.
CDx development collaborations with several life science partners and industry-leading regulatory expertise allow Tempus to submit and maintain the investigational new drug application (IND) for drug development studies.
90+
health systems representing 500+ sites
Our solutions
Multimodal database
Our extensive multimodal database and computational biology expertise enable rapid and data-driven protocol design.
Next generation sequencing and validated AI algorithms
Our scaled clinical sequencing lab and AI-driven algorithms enable you to pre-screen patients for biomarkers of interest and identify potentially eligible patients for studies.
Extensive clinical trial network
Our TIME network enables you to identify potential patients, quickly activate sites, and hit enrollment targets.
CDx capabilities
Our regulatory submission expertise and clinical trial sequencing experience naturally lends itself to downstream CDx development upon study readout.
Collaboration timeline
Our end to end approach has been used to accelerate clinical trial start-up and execution for the PAVO study:
5 months from study hypothesis to IND submission and IRB approval
60 days from IRB approval to first site activated, leveraging our TIME Trial Program, a just-in-time network of providers
10 days from first site activated to first patient dosed
This is AI-enabled precision medicine
This is the future of healthcare.